Imatinib as a paradigm of targeted therapies

被引：45

作者：

Druker, BJ

机构：

[1] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA

[2] Howard Hughes Med Inst, Portland, OR USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 23期

关键词：

D O I：

10.1200/JCO.2003.10.589

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：239S / 245S

页数：7

共 49 条

[1] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[2] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].

BEN-NERIAH, Y ;

DALEY, GQ ;

MESMASSON, AM ;

WITTE, ON ;

BALTIMORE, D .

SCIENCE, 1986, 233 (4760) :212-214

[3]

Bennett JH., 1845, EDINBURGH MED SURG J, P413

[4] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[5] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[6] Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 [J].

Corbin, AS ;

Buchdunger, E ;

Pascal, F ;

Druker, BJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32214-32219

[7] Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib [J].

Corbin, AS ;

La Rosée, P ;

Stoffregen, EP ;

Druker, BJ ;

Deininger, MW .

BLOOD, 2003, 101 (11) :4611-4614

[8] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[9] ACTIVATION OF THE C-ABL-ONCOGENE BY VIRAL TRANSDUCTION OR CHROMOSOMAL TRANSLOCATION GENERATES ALTERED C-ABL-PROTEINS WITH SIMILAR INVITRO KINASE PROPERTIES [J].

DAVIS, RL ;

KONOPKA, JB ;

WITTE, ON .

MOLECULAR AND CELLULAR BIOLOGY, 1985, 5 (01) :204-213

[10] A CELLULAR ONCOGENE IS TRANSLOCATED TO THE PHILADELPHIA-CHROMOSOME IN CHRONIC MYELOCYTIC-LEUKEMIA [J].

DEKLEIN, A ;

VANKESSEL, AG ;

GROSVELD, G ;

BARTRAM, CR ;

HAGEMEIJER, A ;

BOOTSMA, D ;

SPURR, NK ;

HEISTERKAMP, N ;

GROFFEN, J ;

STEPHENSON, JR .

NATURE, 1982, 300 (5894) :765-767

← 1 2 3 4 5 →